国家新版基药目录调整在即，11部门联合发文强化政策衔接

Core Viewpoint - The release of the "National Essential Medicines Directory Management Measures" signals an important adjustment to the national essential medicines list, which has not been updated for eight years, indicating a shift in the drug supply assurance system in China [1][3][5] Group 1: Key Aspects of the New Measures - The new measures improve the directory management mechanism, linking essential medicines supply with tiered diagnosis and treatment, centralized procurement, and reimbursement policies [3] - The selection of drugs will focus on clinical value and will be dynamically adjusted based on changes in disease spectrum, clinical application practices, drug standards, and newly approved drugs [3] - The directory will include only drugs approved by the National Medical Products Administration and those produced according to national standards, with specific exclusions for certain types of drugs [3][4] Group 2: Implications for the Pharmaceutical Industry - The current essential medicines directory, last updated in 2018, includes 685 varieties, and the new measures suggest that many newly approved drugs may soon be included, enhancing market opportunities for innovative drug companies [4][5] - The adjustment of the essential medicines list is expected to emphasize economic evaluations and cost-effectiveness, prompting pharmaceutical companies to adjust their R&D and pricing strategies [5] - The ability of generic drug companies to enter the essential medicines directory through centralized procurement will be crucial for maintaining market share, indicating a significant shift in market competition dynamics [5]